Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 88 peer-reviewed journal articles Updated
Oncology · Post-Transplant Lymphoproliferative Disorder

Understanding Post-Transplant Lymphoproliferative Disorder (PTLD)

At a Glance

Post-Transplant Lymphoproliferative Disorder (PTLD) is a serious immune system disorder triggered by immunosuppression after an organ or stem cell transplant. It is most often linked to the Epstein-Barr Virus (EBV) and requires specialized medical management to balance immune response and graft health.

After the intense journey of a transplant, being told you or your child now faces a serious condition like Post-Transplant Lymphoproliferative Disorder (PTLD) can feel like a profound shock [1][2]. It is important to understand that PTLD is a recognized complication of the very life-saving treatments required for a transplant [3]. While it can behave like a cancer, it is fundamentally a disorder of the immune system that occurs when the “brakes” are taken off certain white blood cells [4].

Why PTLD Happens

To prevent the body from rejecting a new organ or stem cells, you must take immunosuppressive drugs. These medications work by quietening the immune system [5]. However, this also lowers defenses against viruses, most notably the Epstein-Barr Virus (EBV) [3].

EBV is a very common virus—most adults have already been exposed to it, and it usually stays “asleep” in our B-cells (a type of white blood cell) [3][6]. When the immune system is suppressed, the virus can wake up and cause B-cells to grow and multiply out of control, leading to the clusters or tumors known as PTLD [3][7].

Who is at Highest Risk?

The risk of developing PTLD depends largely on the type of transplant and the patient’s history with EBV.

  • EBV-Negative Recipients: The highest risk is for people who have never had EBV (seronegative) and receive an organ or cells from a donor who has had the virus (D+/R- mismatch) [3][7]. Because the recipient’s immune system has never seen the virus before, it has no “memory” to help fight it off when it is introduced during the transplant [7].
  • Pediatric Patients: Children are at exceptionally high risk—sometimes reaching 10-15%—because they are more likely to be EBV-negative at the time of transplant [5][8][2].
  • Transplant Type: The more intense the immunosuppression, the higher the risk.
    • Kidney: 1–3% [1]
    • Liver: 1–5% [1]
    • Heart and Lung: 2–10% [1][9]
    • Multivisceral (multiple organs): Up to 20% [9]
    • Stem Cell (HSCT): 1–3% [10][11]

Timing and Origin: SOT vs. HSCT

There are key differences in how PTLD appears depending on whether the patient had a Solid Organ Transplant (SOT), like a kidney or liver, or a Hematopoietic Stem Cell Transplant (HSCT).

Feature Solid Organ Transplant (SOT) Stem Cell Transplant (HSCT)
Typical Onset Often within the first 1–2 years (Early) or years later (Late) [12][13] Usually very early, often within months of the transplant [14][15]
Cell Origin Usually the patient’s own cells (Host) [16] Usually the donor’s cells [10][17]
EBV Link Very strong in early cases; weaker in late-onset cases [12][18] Almost always linked to EBV reactivation [10]

Understanding the Subtypes

In 2022, the World Health Organization (WHO) updated the way PTLD is classified to help doctors better choose treatments [19][4]. There are four main categories:

  1. Non-destructive PTLD: Small clusters of cells that haven’t yet destroyed the surrounding tissue [4].
  2. Polymorphic PTLD: A mixed collection of different types of immune cells [4][20].
  3. Monomorphic PTLD: The cells all look the same and resemble a specific type of lymphoma (like Diffuse Large B-cell Lymphoma) [4][20].
  4. Classic Hodgkin Lymphoma-type PTLD: A rare form that looks exactly like Hodgkin lymphoma [4][20].

Explore This Guide

To help navigate this diagnosis, we have created specific guides covering every step of the journey:

01

Biology & Pathology: Subtypes and Your Biopsy Report

Learn how to read your PTLD pathology report. Understand the differences between WHO subtypes, excisional biopsies vs FNAs, and what EBER test results mean.

02

Symptoms & Diagnostic Challenges: The Great Mimicker

Learn the symptoms of Post-Transplant Lymphoproliferative Disease (PTLD). Understand B-symptoms, why EBV blood tests aren't enough, and diagnostic challenges.

03

Treatment Strategy: Balancing Your Graft and Your Recovery

Learn about Post-Transplant Lymphoproliferative Disease (PTLD) treatment strategies. Understand RIS, Rituximab, chemotherapy, and how to protect your graft.

04

Prognosis & The Road Ahead: Monitoring for the Long Term

Learn about long-term monitoring after PTLD treatment. Understand risk scores, EBV viral load tests, PET scans, and how to manage the risk of relapse.

Common questions in this guide

What causes PTLD after a transplant?
PTLD is primarily caused by a combination of the immunosuppressive drugs needed to prevent organ rejection and the reactivation of the Epstein-Barr Virus (EBV). The quieted immune system allows EBV-infected white blood cells, known as B-cells, to multiply out of control.
Who is at the highest risk for developing PTLD?
The highest risk is seen in patients who have never been exposed to the Epstein-Barr Virus (EBV) but receive a transplant from a donor who has had the virus. Children are particularly vulnerable because they are more likely to be EBV-negative at the time of their transplant.
Does PTLD behave differently depending on the type of transplant?
Yes. In solid organ transplants, PTLD usually originates from the patient's own cells and can happen early on or years later. In stem cell transplants, PTLD almost always originates from the donor's cells and typically appears within months of the procedure.
What are the different subtypes of PTLD?
The World Health Organization classifies PTLD into four main categories to guide treatment: non-destructive, polymorphic, monomorphic, and classic Hodgkin lymphoma-type. Each subtype looks different under a microscope and behaves differently in the body.
How do doctors treat PTLD?
A common first step in treating PTLD involves carefully reducing a patient's immunosuppressive medications. This allows the immune system to fight the disorder, but doctors must closely balance this with the risk of the body rejecting the transplanted organ.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Was my pre-transplant EBV status positive or negative, and how does that affect my current risk?
  2. 2.Is the PTLD currently being seen of 'host' or 'donor' origin, and why does that matter for the treatment plan?
  3. 3.Which of the four WHO subtypes (non-destructive, polymorphic, monomorphic, or classic Hodgkin lymphoma-type) was found on the biopsy?
  4. 4.What is the current EBV viral load, and how often will it be monitored moving forward?
  5. 5.How will you balance the need to reduce immunosuppression to fight PTLD with the risk of organ rejection?
  6. 6.Are there specific symptoms, like new fevers or swollen glands, that I should be watching for most closely?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (20)
  1. 1

    Gastrointestinal manifestations, risk factors, and management in patients with post-transplant lymphoproliferative disorder: A systematic review.

    Reiche W, Tauseef A, Sabri A, et al.

    World journal of transplantation 2022; (12(8)):268-280 doi:10.5500/wjt.v12.i8.268.

    PMID: 36159076
  2. 2

    Recent Advances in Adult Post-Transplant Lymphoproliferative Disorder.

    Markouli M, Ullah F, Omar N, et al.

    Cancers 2022; (14(23)) doi:10.3390/cancers14235949.

    PMID: 36497432
  3. 3

    Epstein-Barr Virus DNAemia and post-transplant lymphoproliferative disorder in pediatric solid organ transplant recipients.

    Chang YC, Young RR, Mavis AM, et al.

    PloS one 2022; (17(10)):e0269766 doi:10.1371/journal.pone.0269766.

    PMID: 36256635
  4. 4

    EBV and post-transplant lymphoproliferative disorder: a complex relationship.

    El-Mallawany NK, Rouce RH

    Hematology. American Society of Hematology. Education Program 2024; (2024(1)):728-735 doi:10.1182/hematology.2024000583.

    PMID: 39644052
  5. 5

    Impact of antiviral prophylaxis on EBV viremia and posttransplant lymphoproliferative disorders in solid organ transplant recipients: a systematic review and meta-analysis.

    Moghadamnia M, Delroba K, Heidari S, et al.

    Virology journal 2025; (22(1)):11 doi:10.1186/s12985-025-02623-y.

    PMID: 39815274
  6. 6

    Dynamic Presentations of Recurrent Post-Transplant Lymphoproliferative Disorder in a Heart Transplant Recipient: A Rare Case Study.

    Toiv A, Harris KB, Khan MZ, et al.

    ACG case reports journal 2024; (11(11)):e01554 doi:10.14309/crj.0000000000001554.

    PMID: 39568982
  7. 7

    Post-transplant lymphoproliferative disorders, Epstein-Barr virus infection, and disease in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice.

    Allen UD, Preiksaitis JK,

    Clinical transplantation 2019; (33(9)):e13652 doi:10.1111/ctr.13652.

    PMID: 31230381
  8. 8

    Characteristics, management, and outcome of pediatric patients with post-transplant lymphoproliferative disease-A 20 years' experience from Austria.

    Füreder A, Kropshofer G, Benesch M, et al.

    Cancer reports (Hoboken, N.J.) 2021; (4(5)):e1375 doi:10.1002/cnr2.1375.

    PMID: 33755341
  9. 9

    Incidence of de novo Lymphoproliferative Disorders and Hematological Malignancies in Liver Transplant Recipients: An Updated Meta-Analysis.

    Gadour E, Miutescu B, Kuriry H, et al.

    Saudi journal of medicine & medical sciences 2026; (14(1)):23-35 doi:10.4103/sjmms.sjmms_471_25.

    PMID: 41675957
  10. 10

    Frequency, characteristics, and outcome of PTLD after allo-SCT: A multicenter study from the Spanish group of blood and marrow transplantation (GETH).

    García-Cadenas I, Yáñez L, Jarque I, et al.

    European journal of haematology 2019; (102(6)):465-471 doi:10.1111/ejh.13226.

    PMID: 30828868
  11. 11

    Survival outcomes of allogeneic hematopoietic cell transplants with EBV-positive or EBV-negative post-transplant lymphoproliferative disorder, A CIBMTR study.

    Naik S, Riches M, Hari P, et al.

    Transplant infectious disease : an official journal of the Transplantation Society 2019; (21(5)):e13145 doi:10.1111/tid.13145.

    PMID: 31301099
  12. 12

    Different causes of early and late-onset post transplant lymphoproliferative disorder in kidney transplantation patients after 2000.

    Gwon JG, Kim YH, Han DJ

    Asian journal of surgery 2019; (42(4)):551-556 doi:10.1016/j.asjsur.2018.09.002.

    PMID: 30327178
  13. 13

    Non-invasive monitoring associated with B lymphoma cells in post-transplant lymphoproliferative disorder (PTLD) patients: Systematic review.

    Honar N, Shahramian I, Imanieh MH, et al.

    Human antibodies 2022; (30(4)):183-194 doi:10.3233/HAB-220016.

    PMID: 37005883
  14. 14

    Analysis of risk factors for Epstein-Barr virus reactivation and progression to post-transplant lymphoproliferative disorder in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation.

    Jia L, Yang H, Zhou Y, et al.

    Frontiers in pediatrics 2025; (13()):1627990 doi:10.3389/fped.2025.1627990.

    PMID: 40746349
  15. 15

    Risk Factors and Predictive Scoring System For Post-Transplant Lymphoproliferative Disorder after Hematopoietic Stem Cell Transplantation.

    Fujimoto A, Hiramoto N, Yamasaki S, et al.

    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2019; (25(7)):1441-1449 doi:10.1016/j.bbmt.2019.02.016.

    PMID: 30794929
  16. 16

    A Case of Central Nervous System Post-Transplant Lymphoproliferative Disorder Following Haploidentical Stem Cell Transplantation in a Patient With Acute Lymphoblastic Leukemia.

    Zhu H, Li Q, Liu Y, et al.

    Cell transplantation 2022; (31()):9636897221117532 doi:10.1177/09636897221117532.

    PMID: 35979928
  17. 17

    Recipient-derived EBV-positive Monomorphic Plasmacytoma Type Posttransplant Lymphoproliferative Disorder After Allogeneic Stem Cell Transplant for Severe Aplastic Anemia: A Case Report.

    Carden MA, Caltharp S, Yee ME, et al.

    Journal of pediatric hematology/oncology 2016; (38(8)):e310-e314 doi:10.1097/MPH.0000000000000613.

    PMID: 27403771
  18. 18

    The Changing Epidemiology of Posttransplant Lymphoproliferative Disorder in Adult Solid Organ Transplant Recipients Over 30 Years: A Single-center Experience.

    Peters AC, Akinwumi MS, Cervera C, et al.

    Transplantation 2018; (102(9)):1553-1562 doi:10.1097/TP.0000000000002146.

    PMID: 29485513
  19. 19

    Meeting the Challenges of Post-Transplant Lymphoproliferative Disorders After Liver Transplantation in Children: A Proposed Diagnostic and Management Algorithm.

    Rock NM, Bouroumeau A, Papangelopoulou D, et al.

    Pediatric transplantation 2025; (29(3)):e70060 doi:10.1111/petr.70060.

    PMID: 40241239
  20. 20

    New concepts in EBV-associated B, T, and NK cell lymphoproliferative disorders.

    Quintanilla-Martinez L, Swerdlow SH, Tousseyn T, et al.

    Virchows Archiv : an international journal of pathology 2023; (482(1)):227-244 doi:10.1007/s00428-022-03414-4.

    PMID: 36216980

This page provides educational information about Post-Transplant Lymphoproliferative Disorder (PTLD). It is not a substitute for professional medical advice; always consult your transplant team for guidance on your specific risks and care plan.

Get notified when new evidence is published on Post-transplant lymphoproliferative disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.